Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clini...
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial
About this item
Full title
Author / Creator
Patil, Sandeep T , Zhang, Lu , Martenyi, Ferenc , Lowe, Stephen L , Jackson, Kimberley A , Andreev, Boris V , Avedisova, Alla S , Bardenstein, Leonid M , Gurovich, Issak Y , Morozova, Margarita A , Mosolov, Sergey N , Neznanov, Nikolai G , Reznik, Alexander M , Smulevich, Anatoly B , Tochilov, Vladimir A , Johnson, Bryan G , Monn, James A and Schoepp, Darryle D
Publisher
New York: Nature Publishing Group US
Journal title
Language
English
Formats
Publication information
Publisher
New York: Nature Publishing Group US
Subjects
More information
Scope and Contents
Contents
Schizophrenia is a chronic, complex and heterogeneous mental disorder, with pathological features of disrupted neuronal excitability and plasticity within limbic structures of the brain. These pathological features manifest behaviorally as positive symptoms (including hallucinations, delusions and thought disorder), negative symptoms (such as socia...
Alternative Titles
Full title
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial
Authors, Artists and Contributors
Author / Creator
Zhang, Lu
Martenyi, Ferenc
Lowe, Stephen L
Jackson, Kimberley A
Andreev, Boris V
Avedisova, Alla S
Bardenstein, Leonid M
Gurovich, Issak Y
Morozova, Margarita A
Mosolov, Sergey N
Neznanov, Nikolai G
Reznik, Alexander M
Smulevich, Anatoly B
Tochilov, Vladimir A
Johnson, Bryan G
Monn, James A
Schoepp, Darryle D
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_223115629
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_223115629
Other Identifiers
ISSN
1078-8956
E-ISSN
1546-170X
DOI
10.1038/nm1632
